[CAS NO. 745013-59-6] Tremelimumab

Ships within

Stock

Price

Qty

Total

COA

Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.

Catalog:	HY-P9918
Brand:	MCE
CAS:	745013-59-6

Overview

MDL	-
Molecular Weight	-
Molecular Formula	-
SMILES	[Tremelimumab]

For research use only. We do not sell to patients.

Summary

Tremelimumab (Ticilimumab) is a fully humanized monoclonal antibody specific for cytotoxic T-lymphocyte antigen-4 ( CTLA-4 ) and can be used for metastatic melanoma research ^[1] .

In Vitro

Tremelimumab (Ticilimumab) has a higher affinity for CTLA-4-Ig than for CD28-Ig and that the antibody is specific for cynomolgus monkeys and humans ^[1] .
Tremelimumab does not bind to human leukocyte FcγR and does not trigger the release of cytokines avoiding the cytokine release syndrome, but increases the IL-2 production upon stimulation with the staphylococcal enterotoxin A in a concentration-dependent manner ^[1] .
Tremelimumab enhances the IL-2 production in T-cells ^[1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase
NCT01853618	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Heptocellular Cancer\|Biliary Tract Neoplasms\|Liver Cancer\|Hepatocellular Carcinoma\|Biliary Cancer	May 2, 2013	Phase 1\|Phase 2
NCT03101475	European Organisation for Research and Treatment of Cancer - EORTC	Colorectal Cancer\|Liver Metastases	November 23, 2018	Phase 2
NCT02261220	MedImmune LLC	Advanced Solid Tumors	October 13, 2014	Phase 1
NCT03144778	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7\|Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7\|Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7	July 12, 2017	Phase 1
NCT03283605	Centre hospitalier de l´Université de Montréal (CHUM)\|AstraZeneca	Head and Neck Squamous Cell Carcinoma\|Metastatic Squamous Cell Carcinoma	July 17, 2018	Phase 1\|Phase 2
NCT02551159	AstraZeneca	Squamous Cell Carcinoma of the Head and Neck	October 15, 2015	Phase 3
NCT03212469	Gustave Roussy, Cancer Campus, Grand Paris	Head and Neck Squamous Cell Carcinoma\|Lung Cancer\|Oesophageal Cancer	June 20, 2017	Phase 1\|Phase 2
NCT03202758	Centre Georges Francois Leclerc\|AstraZeneca	Colorectal Cancer Metastatic	August 29, 2017	Phase 1\|Phase 2
NCT02705482	MedImmune LLC	Select Advanced Solid Tumors	March 30, 2016	Phase 1
NCT03298451	AstraZeneca	Hepatocellular Carcinoma	October 11, 2017	Phase 3
NCT03598816	Washington University School of Medicine\|MedImmune LLC	Renal Cell Carcinoma	August 31, 2020	Phase 2
NCT03682068	AstraZeneca	Unresectable Locally Advanced Urothelial Cancer\|Metastatic Urothelial Cancer	September 27, 2018	Phase 3
NCT02718911	Eli Lilly and Company\|AstraZeneca	Solid Tumor	June 16, 2016	Phase 1
NCT03452332	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Advanced Cervical Adenocarcinoma\|Advanced Vaginal Carcinoma\|Advanced Vulvar Carcinoma\|Human Papillomavirus-Related Cervical Squamous Cell Carcinoma\|Human Papillomavirus-Related Vulvar Squamous Cell Carcinoma\|Metastatic Cervical Adenocarcinoma\|Metastatic Cervical Carcinoma\|Metastatic Cervical Squamous Cell Carcinoma, Not Otherwise Specified\|Metastatic Vaginal Adenocarcinoma\|Metastatic Vaginal Carcinoma\|Metastatic Vulvar Carcinoma\|Recurrent Cervical Adenocarcinoma\|Recurrent Cervical Carcinoma\|Recurrent Cervical Squamous Cell Carcinoma, Not Otherwise Specified\|Recurrent Vaginal Carcinoma\|Recurrent Vulvar Carcinoma\|Stage III Cervical Cancer AJCC v8\|Stage III Vaginal Cancer AJCC v8\|Stage III Vulvar Cancer AJCC v8\|Stage IIIA Cervical Cancer AJCC v8\|Stage IIIA Vulvar Cancer AJCC v8\|Stage IIIB Cervical Cancer AJCC v8\|Stage IIIB Vulvar Cancer AJCC v8\|Stage IIIC Vulvar Cancer AJCC v8\|Stage IV Cervical Cancer AJCC v8\|Stage IV Vaginal Cancer AJCC v8\|Stage IV Vulvar Cancer AJCC v8\|Stage IVA Cervical Cancer AJCC v8\|Stage IVA Vaginal Cancer AJCC v8\|Stage IVA Vulvar Cancer AJCC v8\|Stage IVB Cervical Cancer AJCC v8\|Stage IVB Vaginal Cancer AJCC v8\|Stage IVB Vulvar Cancer AJCC v8\|Vaginal Squamous Cell Carcinoma, Not Otherwise Specified\|Vulvar Adenocarcinoma\|Vulvar Squamous Cell Carcinoma	July 18, 2018	Phase 1
NCT02754856	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Metastatic Carcinoma in the Liver\|Resectable Mass\|Stage IV Colorectal Cancer AJCC v7\|Stage IVA Colorectal Cancer AJCC v7\|Stage IVB Colorectal Cancer AJCC v7	July 28, 2016	Phase 1
NCT03317158	Noah Hahn, M.D.\|AstraZeneca\|Hoosier Cancer Research Network	Urothelial Carcinoma\|Bladder Cancer	November 21, 2017	Phase 1\|Phase 2
NCT04238637	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest\|AstraZeneca	Intrahepatic Cholangiocarcinoma	November 1, 2019	Phase 2
NCT03539822	Anwaar Saeed\|AstraZeneca\|Exelixis\|University of Kansas Medical Center	Gastric Cancer\|Esophageal Adenocarcinoma\|Hepatocellular Carcinoma\|Colorectal Cancer	October 22, 2018	Phase 1\|Phase 2
NCT04395079	Jonsson Comprehensive Cancer Center\|AstraZeneca	Metastatic Malignant Female Reproductive System Neoplasm\|Platinum-Resistant Malignant Female Reproductive System Neoplasm\|Recurrent Malignant Female Reproductive System Neoplasm\|Refractory Malignant Female Reproductive System Neoplasm	August 7, 2020	Phase 2
NCT03275597	University of Wisconsin, Madison\|AstraZeneca	Non-small Cell Lung Cancer\|Non-small Cell Lung Cancer Stage IV	February 20, 2018	Phase 1
NCT03095274	Grupo Espanol de Tumores Neuroendocrinos	Neuroendocrine Tumors\|Neuroendocrine Neoplasm of Lung	April 11, 2017	Phase 2
NCT02485990	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca\|MedImmune LLC	Primary Peritoneal Carcinoma	January 8, 2016	Phase 1
NCT02821754	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Biliary Tract Neoplasms\|Liver Cancer\|Hepatocellular Carcinoma\|Cholangiocarcinoma\|Bile Duct Cancer	July 5, 2016	Phase 2
NCT02205333	MedImmune LLC	Advanced Solid Tumors\|Aggressive B-cell Lymphomas	August 13, 2014	Phase 1\|Phase 2
NCT03234153	University Hospital Inselspital, Berne\|AstraZeneca	Muscle-invasive Bladder Cancer	July 15, 2018	Phase 2
NCT03085849	Catherine Shu\|Columbia University	Extensive-stage Small Cell Lung Cancer	December 15, 2017	Phase 1
NCT03015129	Memorial Sloan Kettering Cancer Center	Endometrial Cancer\|Endometrial Carcinosarcoma\|Endometrial Carcinoma\|Endometrial Cancer Recurrent\|Endometrial Carcinoma, Recurrent	January 2017	Phase 2
NCT03923270	H. Lee Moffitt Cancer Center and Research Institute\|AstraZeneca	Small Cell Lung Cancer Extensive Stage\|Small-cell Lung Cancer	June 6, 2019	Phase 1
NCT02879162	Canadian Cancer Trials Group\|AstraZeneca	Advanced Rare Tumours	October 19, 2016	Phase 2
NCT02117219	MedImmune LLC	Myelodysplastic Syndrome	May 20, 2014	Phase 1
NCT02735239	Ludwig Institute for Cancer Research\|AstraZeneca	Esophageal Cancer	June 24, 2016	Phase 1\|Phase 2
NCT04817826	Gruppo Oncologico del Nord-Ovest	Gastric Cancer\|Microsatellite Instability	April 1, 2021	Phase 2
NCT02499328	AstraZeneca\|MedImmune LLC	Advanced Solid Tumors & Metastatic Squamous Cell Carcinoma of the Head and Neck	August 6, 2015	Phase 1\|Phase 2
NCT05000710	Sheba Medical Center\|AstraZeneca\|Rambam Health Care Campus\|Tel-Aviv Sourasky Medical Center	Metastatic or Locally Advanced NSCLC	December 9, 2021	Phase 2
NCT03473574	AIO-Studien-gGmbH\|AstraZeneca	Cholangiocarcinoma\|Gall Bladder Carcinoma\|Cholangiocarcinoma Non-resectable\|Gallbladder Carcinoma Non-Resectable	May 2, 2018	Phase 2
NCT02340975	MedImmune LLC	Gastric or Gastroesophageal Junction Adenocarcinoma	March 31, 2015	Phase 1\|Phase 2
NCT04605731	City of Hope Medical Center\|National Cancer Institute (NCI)	BCLC Stage B Hepatocellular Carcinoma\|BCLC Stage C Hepatocellular Carcinoma\|Locally Advanced Hepatocellular Carcinoma\|Stage III Hepatocellular Carcinoma AJCC v8\|Stage IIIA Hepatocellular Carcinoma AJCC v8\|Stage IIIB Hepatocellular Carcinoma AJCC v8\|Stage IV Hepatocellular Carcinoma AJCC v8\|Stage IVA Hepatocellular Carcinoma AJCC v8\|Stage IVB Hepatocellular Carcinoma AJCC v8\|Unresectable Hepatocellular Carcinoma	August 3, 2021	Phase 1
NCT02626130	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Clear Cell Renal Cell Carcinoma\|Metastatic Renal Cell Cancer\|Stage IV Renal Cell Cancer AJCC v7	March 30, 2016	Early Phase 1
NCT02352948	AstraZeneca	Non - Small Cell Lung Cancer NSCLC	January 13, 2015	Phase 3
NCT03518606	UNICANCER\|National Cancer Institute, France\|AstraZeneca\|Pierre Fabre Laboratories	Advanced Solid Tumours\|Breast Cancer\|Head and Neck Cancer\|Cervix Cancer\|Prostate Cancer	June 20, 2018	Phase 1\|Phase 2
NCT02000947	MedImmune LLC	NSCLC\|Non-small Cell Lung Cancer\|Lung Cancer	October 25, 2013	Phase 1
NCT03022500	Seoul National University Hospital	Durvalumab &addition; Tremelimumab Combination Treatment, Pulmonary Sarcomatoid Carcinoma, NSCLC	May 18, 2017	Phase 2
NCT03802747	University of Colorado, Denver\|AstraZeneca	Colorectal Cancer	August 2019	Phase 1
NCT00702923	University of Wisconsin, Madison\|Pfizer	Prostate Cancer	July 2008	Phase 1
NCT03959293	Federation Francophone de Cancerologie Digestive\|AstraZeneca	Gastric Adenocarcinoma\|Gastric Cancer	July 17, 2019	Phase 2
NCT03549715	Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie	Infiltrating Bladder Urothelial Carcinoma	December 6, 2018	Phase 1\|Phase 2
NCT03007407	NSABP Foundation Inc	Colorectal Cancer Metastatic	July 31, 2017	Phase 2
NCT03075527	Dana-Farber Cancer Institute\|AstraZeneca	Mesothelioma	April 10, 2017	Phase 2
NCT02639026	Abramson Cancer Center of the University of Pennsylvania	Metastatic\|Melanoma\|Non Small Cell Lung Cancer (NSCLC)\|Breast Cancer\|Pancreatic Cancer	January 26, 2016	Phase 1
NCT03043872	AstraZeneca	Small Cell Lung Carcinoma Extensive Disease	March 27, 2017	Phase 3
NCT03509012	AstraZeneca	Carcinoma, Squamous Cell of Head and Neck\|Carcinoma, Non-Small-Cell Lung\|Small Cell Lung Carcinoma	May 2, 2018	Phase 1
NCT02369874	AstraZeneca	Recurrent or Metastatic PD-L1-positive or -Negative Squamous Cell Carcinoma of the Head and Neck SCCHN	September 9, 2015	Phase 3
NCT01975831	Ludwig Institute for Cancer Research\|MedImmune LLC\|Cancer Research Institute, New York City	Breast Cancer\|Ovarian Cancer\|Colorectal Cancer\|Cervical Cancer\|Renal Cell Carcinoma	December 19, 2013	Phase 1
NCT00897312	Vanderbilt-Ingram Cancer Center\|National Cancer Institute (NCI)	Melanoma	October 2006
NCT02586987	AstraZeneca	Lung Cancer\|Melanoma\|Head and Neck Carcinoma\|Gastroesophageal Cancer\|Breast Cancer\|Pancreatic Adenocarcinoma\|Colorectal Cancer\|Biliary Tract Cancer	December 28, 2015	Phase 1
NCT03057106	Canadian Cancer Trials Group\|AstraZeneca\|Fondazione IRCCS Istituto Nazionale dei Tumori, Milano\|National Health and Medical Research Council, Australia	Lung Cancer Metastatic	February 15, 2017	Phase 2
NCT03430895	Memorial Sloan Kettering Cancer Center\|AstraZeneca	Non-Transitional Cell Carcinoma of the Urothelial Tract\|Small Cell of the Bladder\|Adenocarcinoma of the Bladder\|Squamous Cell Carcinoma of the Bladder\|Metastatic Bladder Cancer	January 31, 2018	Phase 2
NCT03482102	Massachusetts General Hospital\|AstraZeneca	Hepatocellular Carcinoma\|Biliary Tract Cancer	May 14, 2018	Phase 2
NCT03911557	John L. Villano, MD, PhD\|University of Kentucky	Tumor, Solid	June 8, 2019	Phase 2
NCT02962063	Memorial Sloan Kettering Cancer Center\|AstraZeneca	Esophageal Adenocarcinoma\|Gastroesophageal Junction Adenocarcinoma	November 2016	Phase 1\|Phase 2
NCT01103635	Abramson Cancer Center of the University of Pennsylvania	Recurrent Melanoma\|Stage IV Melanoma	February 2010	Phase 1
NCT03450967	Samsung Medical Center	Head and Neck Squamous Cell Carcinoma	April 11, 2018	Phase 2
NCT02888743	National Cancer Institute (NCI)	Metastatic Colorectal Carcinoma\|Metastatic Lung Non-Small Cell Carcinoma\|Stage IV Colorectal Cancer AJCC v7\|Stage IV Lung Non-Small Cell Cancer AJCC v7\|Stage IVA Colorectal Cancer AJCC v7\|Stage IVB Colorectal Cancer AJCC v7	June 6, 2017	Phase 2
NCT03319316	European Organisation for Research and Treatment of Cancer - EORTC	Squamous Non-small Cell Lung Cancer\|Non-Squamous Non-small Cell Lung Cancer	November 1, 2018	Phase 2
NCT03703297	AstraZeneca	Small Cell Lung Cancer	September 27, 2018	Phase 3
NCT03410615	Canadian Cancer Trials Group\|AstraZeneca	Oropharyngeal Squamous Cell Carcinoma	January 31, 2018	Phase 2
NCT03005002	City of Hope Medical Center\|National Cancer Institute (NCI)	Metastatic Carcinoma in the Liver\|MLH1 Gene Mutation\|MSH6 Gene Mutation\|PMS2 Gene Mutation\|Stage IV Colorectal Cancer\|Stage IVA Colorectal Cancer\|Stage IVB Colorectal Cancer	June 28, 2017	Phase 1
NCT02701400	Emory University\|AstraZeneca	Recurrent Small Cell Lung Carcinoma	April 14, 2016	Phase 2
NCT05027425	Davendra Sohal\|University of Cincinnati	Hepatocellular Carcinoma\|Cirrhosis\|Portal Hypertension	December 7, 2021	Phase 2
NCT05345678	AstraZeneca	Unresectable Hepatocellular Carcinoma
NCT03206073	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Colorectal Cancer\|Colorectal Carcinoma\|Colorectal Adenocarcinoma\|Refractory Cancer\|Colorectal Neoplasms	December 7, 2017	Phase 1\|Phase 2
NCT02716805	Ludwig Institute for Cancer Research\|MedImmune LLC\|Cancer Research Institute, New York City\|Multiple Myeloma Research Foundation	Multiple Myeloma	December 13, 2016	Phase 1
NCT02549651	MedImmune LLC	Diffuse Large B-Cell Lymphoma	July 13, 2016	Phase 1
NCT02301130	Kyowa Kirin, Inc.\|AstraZeneca	Advanced Solid Tumors	November 26, 2014	Phase 1
NCT04034927	National Cancer Institute (NCI)\|NRG Oncology	Fallopian Tube Endometrioid Tumor\|Fallopian Tube High Grade Serous Adenocarcinoma\|Malignant Ovarian Endometrioid Tumor\|Ovarian High Grade Serous Adenocarcinoma\|Platinum-Sensitive Fallopian Tube Carcinoma\|Platinum-Sensitive Ovarian Carcinoma\|Platinum-Sensitive Primary Peritoneal Carcinoma\|Primary Peritoneal High Grade Serous Adenocarcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Fallopian Tube Endometrioid Adenocarcinoma\|Recurrent Ovarian Endometrioid Adenocarcinoma\|Recurrent Ovarian Serous Adenocarcinoma\|Recurrent Primary Peritoneal Carcinoma\|Recurrent Primary Peritoneal Endometrioid Adenocarcinoma	October 11, 2019	Phase 2
NCT03702179	Spanish Oncology Genito-Urinary Group\|AstraZeneca\|MFAR	Invasive Bladder Cancer	November 19, 2018	Phase 2
NCT02040064	Gustave Roussy, Cancer Campus, Grand Paris\|AstraZeneca	Non Small Cell Lung Cancer	January 2014	Phase 1
NCT05383001	AIO-Studien-gGmbH\|AstraZeneca	NSCLC Stage IV	May 20, 2022	Phase 2
NCT03164772	Ludwig Institute for Cancer Research\|Cancer Research Institute (CRI)\|Boehringer Ingelheim\|MedImmune LLC\|CureVac\|PharmaJet, Inc.	Metastatic Non-small Cell Lung Cancer\|NSCLC	December 20, 2017	Phase 1\|Phase 2
NCT04430452	Mary Feng, MD\|AstraZeneca\|University of California, San Francisco	Advanced Hepatocellular Carcinoma\|Stage III Hepatocellular Carcinoma AJCC v8\|Stage IIIA Hepatocellular Carcinoma AJCC v8\|Stage IIIB Hepatocellular Carcinoma AJCC v8\|Stage IV Hepatocellular Carcinoma AJCC v8\|Stage IVA Hepatocellular Carcinoma AJCC v8\|Stage IVB Hepatocellular Carcinoma AJCC v8	February 4, 2022	Phase 2
NCT02953457	Roswell Park Cancer Institute\|AstraZeneca	BRCA1 Gene Mutation\|BRCA2 Gene Mutation\|Ovarian Serous Adenocarcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma	June 29, 2017	Phase 2
NCT03204812	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Castration-Resistant Prostate Carcinoma\|Metastatic Malignant Neoplasm in the Bone\|Prostate Adenocarcinoma\|Stage IV Prostate Cancer AJCC v8\|Stage IVA Prostate Cancer AJCC v8\|Stage IVB Prostate Cancer AJCC v8	July 14, 2017	Phase 2
NCT02141347	AstraZeneca	Part A and B: Advanced Solid Malignancies\|Part C: Malignant Mesothelioma	May 22, 2014	Phase 1
NCT02812420	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Hydronephrosis\|Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant\|Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant\|Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant\|Infiltrating Renal Pelvis Urothelial Carcinoma, Sarcomatoid Variant\|Renal Pelvis Urothelial Carcinoma\|Stage II Bladder Urothelial Carcinoma AJCC v6 and v7\|Stage II Renal Pelvis Cancer AJCC v7\|Stage II Ureter Cancer AJCC v7\|Stage II Urethral Cancer AJCC v7\|Stage III Bladder Urothelial Carcinoma AJCC v6 and v7\|Stage III Renal Pelvis Cancer AJCC v7\|Stage III Ureter Cancer AJCC v7\|Stage III Urethral Cancer AJCC v7\|Stage IV Renal Pelvis Cancer AJCC v7\|Stage IV Ureter Cancer AJCC v7\|Stage IV Urethral Cancer AJCC v7\|Ureter Urothelial Carcinoma\|Urethral Urothelial Carcinoma	March 7, 2017	Early Phase 1
NCT04159974	University of Cologne\|AstraZeneca	Esophageal Adenocarcinoma	September 30, 2019	Phase 2
NCT05301842	AstraZeneca	Hepatocellular Carcinoma	March 28, 2022	Phase 3
NCT04221555	Asan Medical Center	Resectable Gastric or Gastroesophageal Junction Adenocarcinoma	May 13, 2020	Phase 2
NCT02937818	AstraZeneca	Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma	November 28, 2016	Phase 2
NCT02938793	Prisma Health-Upstate\|AstraZeneca\|MedImmune LLC	Cancer\|Rare Disease	December 1, 2016	Phase 2
NCT03385655	Canadian Cancer Trials Group\|Canadian Cancer Clinical Trials Network\|BC Cancer Foundation	Prostate Cancer	December 12, 2017	Phase 2
NCT03871036	The Netherlands Cancer Institute\|AstraZeneca	Urothelial Carcinoma	May 1, 2019	Phase 1\|Phase 2
NCT02588131	Italian Network for Tumor Biotherapy Foundation\|AstraZeneca	Pleural Mesothelioma\|Peritoneal Mesothelioma	October 2015	Phase 2
NCT04169841	Centre Georges Francois Leclerc\|AstraZeneca	Immunotherapy	February 10, 2020	Phase 2
NCT02563925	Memorial Sloan Kettering Cancer Center\|MedImmune LLC	Metastatic Breast Cancer	September 18, 2015	Not Applicable
NCT03581487	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Recurrent Lung Non-Small Cell Carcinoma\|Stage IV Lung Cancer AJCC v8\|Stage IVA Lung Cancer AJCC v8\|Stage IVB Lung Cancer AJCC v8	April 1, 2019	Phase 1\|Phase 2
NCT03132467	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	Anatomic Stage II Breast Cancer AJCC v8\|Anatomic Stage IIA Breast Cancer AJCC v8\|Anatomic Stage IIB Breast Cancer AJCC v8\|Anatomic Stage III Breast Cancer AJCC v8\|Anatomic Stage IIIA Breast Cancer AJCC v8\|Anatomic Stage IIIB Breast Cancer AJCC v8\|Anatomic Stage IIIC Breast Cancer AJCC v8\|Estrogen Receptor Positive\|HER2+Neu Negative\|Progesterone Receptor Positive\|Prognostic Stage II Breast Cancer AJCC v8\|Prognostic Stage IIA Breast Cancer AJCC v8\|Prognostic Stage IIB Breast Cancer AJCC v8\|Prognostic Stage III Breast Cancer AJCC v8\|Prognostic Stage IIIA Breast Cancer AJCC v8\|Prognostic Stage IIIB Breast Cancer AJCC v8\|Prognostic Stage IIIC Breast Cancer AJCC v8	June 13, 2017	Early Phase 1
NCT03046862	Seoul National University Hospital	Biliary Tract Neoplasms	February 25, 2017	Phase 2
NCT05380713	University Health Network, Toronto\|OICR	Mesothelioma, Malignant	May 9, 2022	Phase 2
NCT02535078	Immunocore Ltd\|AstraZeneca	Malignant Melanoma	November 2015	Phase 1\|Phase 2
NCT03150836	Terence Friedlander, MD\|MedImmune LLC\|University of California, San Francisco	Bladder Cancer	October 1, 2017	Phase 2
NCT05063565	Boston Scientific Corporation\|Biocompatibles UK Ltd	Hepatocellular Carcinoma	December 2022	Phase 2
NCT03975114	National Cancer Institute, Naples\|University of Campania Luigi Vanvitelli\|AstraZeneca	Carcinoma, Non-Small-Cell Lung	December 20, 2018	Phase 2
NCT05120622	University of British Columbia	Bladder Cancer\|High-Risk Cancer\|Tremelimumab\|Durvalumab\|Non-muscle Invasive	September 1, 2021	Phase 1\|Phase 2
NCT03638141	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca	Intermediate Stage of Hepatocellular Carcinoma\|Hepatocellular Carcinoma	October 2, 2019	Phase 2
NCT04287894	The Netherlands Cancer Institute\|AstraZeneca	Stage III NSCLC	December 28, 2018	Phase 1
NCT03737968	Yonsei University	Stage II-IVB Operable HNSCC Oral Cavity\|Hypopharynx\|Oropharynx\|Larynx	January 2, 2019	Phase 2
NCT01843374	MedImmune LLC	Unresectable Pleural or Peritoneal Malignant Mesothelioma	May 17, 2013	Phase 2
NCT02592551	Baylor College of Medicine	Mesothelioma	May 11, 2016	Phase 2
NCT05440864	University Health Network, Toronto\|Clinica Universidad de Navarra, Universidad de Navarra\|University of Milan	Hepatocellular Carcinoma	January 2023	Phase 2
NCT03373760	Southwest Oncology Group\|National Cancer Institute (NCI)	Recurrent Squamous Cell Lung Carcinoma\|Stage IV Squamous Cell Lung Carcinoma AJCC v7	October 2, 2017	Phase 2
NCT03158064	Memorial Sloan Kettering Cancer Center\|AstraZeneca	Germ Cell Tumor\|Nonseminomatous Germ Cell Tumor\|Seminoma\|Germinomatous Germ Cell Tumor\|Dysgerminoma\|Pineal Germ Cell Tumor	May 15, 2017	Phase 2
NCT02819596	Queen Mary University of London\|Vall d´Hebron Institute of Oncology\|AstraZeneca	Renal Clear Cell Carcinoma\|Renal Papillary Cell Carcinoma	January 2017	Phase 2
NCT03122509	Memorial Sloan Kettering Cancer Center\|MedImmune LLC\|AstraZeneca	Metastatic Colorectal Cancer	April 24, 2017	Phase 2
NCT02262741	MedImmune LLC	Squamous Cell Carcinoma of the Head and Neck	October 15, 2014	Phase 1
NCT02643303	Ludwig Institute for Cancer Research\|MedImmune LLC\|Cancer Research Institute, New York City	Head and Neck Squamous Cell Carcinoma\|Breast Cancer\|Sarcoma\|Merkel Cell Carcinoma\|Cutaneous T-Cell Lymphoma\|Melanoma\|Renal Cancer\|Bladder Cancer\|Prostate Cancer\|Testicular Cancer\|Solid Tumor	December 28, 2016	Phase 1\|Phase 2
NCT03277482	Dana-Farber Cancer Institute\|AstraZeneca	Recurrent Gynecological Cancer\|Metastatic Cervical Cancer\|Metastatic Ovarian Cancer\|Metastatic Vaginal Cancer\|Metastatic Vulvar Cancer\|Metastatic Endometrial Cancer\|Recurrent Cervical Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Vaginal Cancer\|Recurrent Vulvar Cancer\|Recurrent Endometrial Cancer	June 1, 2018	Phase 1
NCT05239169	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	Biliary Tract Cancer (CCA)\|Intrahepatic Cholangiocarcinoma\|Hilar Cholangiocarcinoma\|Distal Cholangiocarcinoma\|Gall Bladder Carcinoma	May 23, 2022	Phase 2
NCT02537418	Canadian Cancer Trials Group\|AstraZeneca	Solid Malignancies	October 1, 2015	Phase 1
NCT01655888	Azienda Ospedaliera Universitaria Senese\|MedImmune LLC	Malignant Mesothelioma	July 2012	Phase 2
NCT03084471	AstraZeneca	Advanced Solid Malignancies	June 5, 2017	Phase 3
NCT02815995	M.D. Anderson Cancer Center\|MedImmune LLC	Advanced and+or Metastatic Sarcoma	August 16, 2016	Phase 2
NCT03693612	GlaxoSmithKline\|MedImmune LLC	Neoplasms	November 26, 2018	Phase 1\|Phase 2
NCT05154994	University of Utah\|National Cancer Institute (NCI)	Infiltrating Urothelial Carcinoma, Sarcomatoid Variant\|Locally Advanced Urothelial Carcinoma\|Metastatic Urothelial Carcinoma\|Unresectable Urothelial Carcinoma	January 14, 2022	Phase 1
NCT02516241	AstraZeneca	Urothelial Cancer	November 2, 2015	Phase 3
NCT04073160	Daniel George, MD\|AstraZeneca\|Duke University	Bladder Cancer	June 2020	Phase 1
NCT02453282	AstraZeneca	Non-Small-Cell Lung Carcinoma NSCLC	July 21, 2015	Phase 3
NCT02311361	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Pancreatic Neoplasms\|Pancreatic Cancer\|Cancer of Pancreas\|Cancer of the Pancreas\|Pancreas Cancer	March 25, 2015	Phase 1\|Phase 2
NCT03522584	University of Washington\|National Cancer Institute (NCI)\|AstraZeneca	Metastatic Head and Neck Squamous Cell Carcinoma\|Recurrent Head and Neck Squamous Cell Carcinoma	May 17, 2018	Phase 1\|Phase 2
NCT03994393	University of Sydney\|AstraZeneca\|Australasian Lung Cancer Trials Group	EGFR Mutant Advanced Non Small Cell Lung Cancer	October 23, 2018	Phase 2
NCT02978482	AstraZeneca	Advanced Malignancy	December 1, 2016	Phase 1
NCT04960709	AstraZeneca	Muscle Invasive Bladder Cancer	October 20, 2017	Phase 3
NCT02141542	F. Stephen Hodi, MD\|MedImmune LLC\|Dana-Farber Cancer Institute	Metastatic Melanoma	May 2014	Phase 1
NCT03847649	Canadian Cancer Trials Group\|AstraZeneca	Cancer	June 7, 2019	Phase 2
NCT03081923	Fondazione IRCCS Istituto Nazionale dei Tumori, Milano\|AstraZeneca	Germ Cell Tumor	February 1, 2017	Phase 2
NCT02527434	AstraZeneca	Urothelial Bladder Cancer\|Triple-negative Breast Cancer\|Pancreatic Ductal Adenocarcinoma	November 2, 2015	Phase 2
NCT03601455	Jonsson Comprehensive Cancer Center\|AstraZeneca	Bladder Urothelial Carcinoma\|Stage IV Bladder Cancer AJCC v8\|Stage IVA Bladder Cancer AJCC v8\|Stage IVB Bladder Cancer AJCC v8	October 26, 2018	Phase 2
NCT02179671	AstraZeneca\|Quintiles, Inc.	Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)	July 25, 2014	Phase 2
NCT02879318	Canadian Cancer Trials Group\|AstraZeneca	Pancreatic Adenocarcinoma	August 22, 2016	Phase 2
NCT02868632	NYU Langone Health\|AstraZeneca	Pancreatic Cancer	August 7, 2016	Phase 1
NCT03704480	GERCOR - Multidisciplinary Oncology Cooperative Group\|AstraZeneca	Advanced Biliary Tract Carcinoma	November 9, 2018	Phase 2
NCT03624231	Ulrich Keilholz\|Charite University, Berlin, Germany\|AstraZeneca	Squamous Cell Carcinoma of the Head and Neck	August 15, 2018	Phase 2
NCT04274816	A.J.M. van den Eertwegh\|Amsterdam UMC, location VUmc	Cutaneous Melanoma	July 10, 2012	Phase 1
NCT05451043	AHS Cancer Control Alberta	Pancreatic Cancer\|Hepatocellular Cancer\|Biliary Tract Cancer\|Cholangiocarcinoma	October 1, 2022	Phase 2
NCT03426657	University of Erlangen-Nürnberg Medical School	Locally Advanced Head and Neck Squamous Cell Carcinoma	September 20, 2018	Phase 2
NCT04156087	Baki Topal\|AstraZeneca\|University Hospital, Gasthuisberg	Pancreatic Cancer Non-resectable	May 9, 2020	Phase 2
NCT01938612	AstraZeneca	Advanced Solid Tumors	September 12, 2013	Phase 1
NCT03965468	ETOP IBCSG Partners Foundation\|AstraZeneca	Non-small Cell Lung Cancer\|Stage IV\|Oligometastasis	November 19, 2019	Phase 2
NCT03606967	National Cancer Institute (NCI)	Anatomic Stage IV Breast Cancer AJCC v8\|Invasive Breast Carcinoma\|Metastatic Triple-Negative Breast Carcinoma	December 14, 2018	Phase 2
NCT03122496	Memorial Sloan Kettering Cancer Center\|AstraZeneca	Metastatic Anaplastic Thyroid Cancer	April 25, 2017	Phase 1
NCT03164616	AstraZeneca	Non Small Cell Lung Cancer NSCLC	June 1, 2017	Phase 3
NCT03937830	National Cancer Institute (NCI)\|National Institutes of Health Clinical Center (CC)	Hepatocellular Cancer\|Hepatocellular Carcinoma\|Metastatic Hepatocellular Carcinoma	March 10, 2021	Phase 2
NCT03753919	Grupo Espanol de Tumores Neuroendocrinos\|MFAR	Metastatic Thyroid Papillary Carcinoma\|Metastatic Thyroid Follicular Carcinoma\|Metastatic Thyroid Cancer	April 2, 2019	Phase 2
NCT02154490	Southwest Oncology Group\|National Cancer Institute (NCI)	Recurrent Squamous Cell Lung Carcinoma\|Stage IV Squamous Cell Lung Carcinoma AJCC v7	June 16, 2014
NCT04625699	Catherine Shu\|Columbia University	Nonsmall Cell Lung Cancer	December 2022	Phase 2
NCT02319044	AstraZeneca\|PRA Health Sciences	Recurrent+Metastatic Squamous Cell Carcinoma of Head & Neck	April 15, 2015	Phase 2
NCT03699449	Yonsei University\|AstraZeneca\|Samsung Genomic Institute\|Seoul National University Hospital\|Samsung Medical Center\|Korean Gynecologic Oncology Group	Platinum-resistant Recurrent Ovarian Cancer	November 26, 2018	Phase 2
NCT03982173	Gustave Roussy, Cancer Campus, Grand Paris	Metastatic Colorectal Cancer\|Triple Negative Breast Cancer\|Prostate Adenocarcinoma\|Stomach Adenocarcinoma\|Esophageal Adenocarcinoma	April 15, 2019	Phase 2
NCT05557838	AstraZeneca	Hepatocellular Carcinoma	November 30, 2022	Phase 3
NCT03026062	M.D. Anderson Cancer Center	Platinum-Resistant Fallopian Tube Carcinoma\|Platinum-Resistant Ovarian Carcinoma\|Platinum-Resistant Primary Peritoneal Carcinoma\|Recurrent Fallopian Tube Carcinoma\|Recurrent Ovarian Carcinoma\|Recurrent Primary Peritoneal Carcinoma\|Refractory Fallopian Tube Carcinoma\|Refractory Ovarian Carcinoma\|Refractory Primary Peritoneal Carcinoma	May 18, 2017	Phase 2
NCT02788773	Canadian Cancer Trials Group\|AstraZeneca	Prostate Cancer	August 18, 2016	Phase 2
NCT02870920	Canadian Cancer Trials Group\|AstraZeneca	Colorectal Cancer	August 10, 2016	Phase 2
NCT03784066	Universitaire Ziekenhuizen KU Leuven\|AstraZeneca\|European Organisation for Research and Treatment of Cancer - EORTC\|Vlaams Instituut voor Biotechnologie (VIB)	Oral Cavity Squamous Cell Carcinoma	August 27, 2018	Phase 1\|Phase 2
NCT04107168	CCTU- Cancer Theme\|Microbiotica Ltd\|Cambridge University Hospitals NHS Foundation Trust	Melanoma\|Renal Cancer\|Lung Cancer	July 8, 2020
NCT03472274	Fundacion CRIS de Investigación para Vencer el Cáncer\|AstraZeneca\|Apices Soluciones S.L.	Bladder Cancer	October 25, 2018	Phase 2
NCT03288532	University College, London\|AstraZeneca\|Kidney Cancer UK\|Cancer Research UK	Renal Cell Carcinoma	July 19, 2018	Phase 3
NCT03608865	Yonsei University	Metastatic Breast Cancer	September 19, 2017	Phase 2
NCT03237377	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins\|AstraZeneca	Non-Small Cell Lung Cancer	December 12, 2017	Phase 2
NCT03963414	Vinicius Ernani\|AstraZeneca\|University of Nebraska	Small Cell Lung Carcinoma	June 5, 2020	Phase 1
NCT02571725	New Mexico Cancer Care Alliance	Ovarian Cancer\|Fallopian Tube Cancer\|Peritoneal Neoplasms	February 23, 2016	Phase 1\|Phase 2
NCT03317457	AIO-Studien-gGmbH\|AstraZeneca	Metastatic Adult Soft Tissue Sarcoma\|Recurrent Adult Soft Tissue Sarcoma	December 15, 2017	Phase 2
NCT01649024	Azienda Ospedaliera Universitaria Senese	Malignant Mesothelioma	May 2009	Phase 2
NCT03837899	AstraZeneca	Pediatric Cancer\|Solid Tumor Pediatric\|Hematological Malignancies	March 7, 2019	Phase 1\|Phase 2
NCT02762006	Moshe Ornstein\|Case Comprehensive Cancer Center	Renal Cell Carcinoma\|Kidney Cancer	December 20, 2016	Phase 1
NCT02616185	Pfizer	Prostatic Neoplasms	December 30, 2015	Phase 1
NCT04988945	The University of Hong Kong	HCC	December 1, 2020	Phase 2
NCT03089645	MedImmune LLC	Advanced Solid Tumors	March 21, 2017	Phase 1
NCT02794883	Northwestern University\|AstraZeneca\|MedImmune LLC\|National Cancer Institute (NCI)	Malignant Glioma\|Recurrent Glioblastoma	November 1, 2016	Phase 2
NCT03618134	Jonsson Comprehensive Cancer Center\|AstraZeneca	Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8\|Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8\|Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8\|Human Papillomavirus Positive\|Oropharyngeal Squamous Cell Carcinoma\|p16 Positive Neoplastic Cells Present\|Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8\|Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8\|Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8	October 4, 2018	Phase 1\|Phase 2
NCT04522544	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest\|AstraZeneca	Hepatocellular Carcinoma Non-resectable	December 15, 2020	Phase 2
NCT02536794	Northwestern University\|MedImmune LLC\|Avon Breast Cancer Foundation\|National Cancer Institute (NCI)	Estrogen Receptor Negative\|Estrogen Receptor Positive\|HER2+Neu Negative\|Recurrent Breast Carcinoma\|Stage IV Breast Cancer	January 14, 2016	Phase 2
NCT02658214	AstraZeneca	Small Cell Lung Carcinoma\|Carcinoma, Squamous Cell of Head and Neck\|Stomach Neoplasms\|Triple Negative Breast Neoplasms\|Ovarian Neoplasms\|Fallopian Tube Neoplasms\|Peritoneal Neoplasms\|Esophagogastric Junction Neoplasms\|Carcinoma, Pancreatic Ductal\|Esophageal Squamous Cell Carcinoma	April 28, 2016	Phase 1
NCT03130764	Columbia University	Non-small Cell Lung Cancer	March 2017	Phase 2
NCT00378482	AstraZeneca	Colorectal Neoplasms\|Melanoma\|Prostatic Neoplasms\|Renal Cell Carcinoma\|Neoplasms\|Patients Who Have+Have Had Melanoma and Other Tumors	March 5, 2007	Phase 2
NCT02519348	MedImmune LLC	Hepatocellular Carcinoma	October 19, 2015	Phase 2
NCT02029001	Centre Leon Berard\|National Cancer Institute, France	Malignant Solid Neoplasms	March 2014	Phase 2
NCT03557918	Matthew Galsky\|AstraZeneca\|Hoosier Cancer Research Network	Urothelial Carcinoma	November 12, 2018	Phase 2

Appearance

Liquid

Shipping

Shipping with dry ice.

Storage

Please store the product under the recommended conditions in the Certificate of Analysis.

References

[1] Comin-Anduix B, et al. Tremelimumab: research and clinical development. Onco Targets Ther. 2016 Mar 23;9:1767-76.

Request a Quote

Please fill in your details below to request a COA for our product. We will send the COA to the provided email address promptly.

Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.

Information

Shipping
Privacy notice
Terms of Service
About us
Contact us

Customer service

Search
Custom Synthesis

My account

My account
Orders
Addresses
Shopping cart